ImmunoEdge is advancing the discovery of tumor-derived immune targets. We’ve developed a novel peptide capture technology that improves detection of HLA-presented peptides — revealing a broader and more immunologically relevant landscape, especially from low-input tumor biopsies. Many promising immune targets are currently missed due to limitations in standard methods. By increasing visibility into this hidden layer of tumor biology, ImmunoEdge supports better target discovery, TCR design, and the development of next-generation immunotherapies. We are guided by a Scientific Advisory Board including Prof. Oreste Acuto (Oxford), a leading expert in T-cell signaling, and Dr. Christophe Masselon (CEA), specialist in mass spectrometry instrumentation and bioanalytical methods.
| Website | https://www.immunoedge.de/ |
| Employees | View employees |
| Founded | 2024 |
| Industry | Hospitals and Health Care |
Looking for a particular ImmunoEdge employee's phone or email?
ImmunoEdge Questions
